Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
Lisinopril	O
/	O
IV	O
Dye,	O
Iodine	O
Containing	O
Contrast	O
Media	O
/	O
vancomycin	O
/	O
Nafcillin	O
/	O
Bumex	O
Attending:	O
___.	O
Chief	O
Complaint:	O
dyspnea,	O
weight	O
gain,	O
___	O
edema	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
___	O
EMR	O
of	O
3cm	O
duodenal	O
adenoma	O
-	O
2	O
clips	O
placed	O
___	O
Temp	O
HD	O
line	O
placement	O
___	O
R	O
thoracentesis	O
___	O
L	O
thoracentesis	O
History	O
of	O
Present	O
Illness:	O
Mr.	O
___	O
is	O
a	O
___	O
y.o.	O
male	O
patient	O
with	O
HFpEF	O
(EF	O
57%	O
___,	O
CAD,	O
HTN,	O
PVD	O
(s/p	O
b/l	O
femoral	O
bypass	O
___,	O
IDDM	O
c/b	O
neuropathy	O
+	O
L	O
plantar	O
foot	B-Pressure_injury
ulcer,	B-Pressure_injury
and	O
Stage	O
3	O
CKD	O
with	O
recent	O
admission	O
___	O
for	O
CHF	O
exacerbation	O
who	O
presented	O
to	O
ED	O
on	O
___	O
for	O
dyspnea,	O
reported	O
weight	O
gain,	O
lower	O
extremity	O
edema	O
and	O
was	O
subsequently	O
admitted	O
to	O
Inpatient	O
HF	O
Service	O
on	O
___	O
for	O
acute	O
decompensated	O
HFrEF	O
and	O
___	O
on	O
Stage	O
3	O
CKD.	O
Over	O
the	O
past	O
___	O
days,	O
he	O
reports	O
worsening	O
dyspnea	O
(not	O
on	O
home	O
O2),	O
lower	O
extremity	O
swelling,	O
poor	O
appetite,	O
fatigue,	O
and	O
weight	O
gain	O
of	O
~8	O
lbs	O
(232	O
>	O
240	O
lbs).	O
On	O
___,	O
he	O
took	O
metolazone	O
2.5mg	O
as	O
directed	O
by	O
Cardiology.	O
On	O
___,	O
he	O
began	O
taking	O
metolazone	O
5mg	O
+	O
KCl	O
30mEq	O
x1	O
per	O
Dr	O
___	O
on	O
___	O
in	O
conjunction	O
with	O
his	O
torsemide	O
to	O
address	O
his	O
weight	O
gain.	O
Despite	O
taking	O
diuretics,	O
he	O
reported	O
decreased	O
urination.	O
Usually	O
he	O
voids	O
___	O
he	O
continued	O
voiding	O
as	O
much,	O
but	O
noticed	O
he	O
was	O
making	O
~5cc	O
urine	O
with	O
each	O
void.	O
Notably,	O
he	O
was	O
recently	O
admitted	O
and	O
prior	O
to	O
this	O
on	O
___	O
for	O
ADHFpEF	O
(Diuresed	O
with	O
IV	O
boluses	O
160mg	O
bid,	O
Lasix	O
gtt@10mg/hr	O
>	O
d/c	O
weight:	O
259lbs	O
on	O
PO	O
Torsemide	O
80mg	O
qd).	O
Discharge	O
weight	O
was	O
106.9	O
kg	O
(235.67	O
lb)	O
(dry	O
weight	O
thought	O
to	O
be	O
~133	O
lbs)	O
and	O
discharge	O
Cr	O
was	O
2.7.	O
Additionally,	O
he	O
reports	O
___	O
loose	O
stools	O
over	O
the	O
past	O
few	O
days.	O
Grandkids	O
have	O
been	O
sick,	O
but	O
no	O
recent	O
GI	O
illnesses	O
or	O
travel	O
history.	O
Reports	O
brown	O
stools	O
recently,	O
though	O
had	O
melena	B-Upper_gastrointestinal_haemorrhage
while	O
on	O
Eliquis	O
(started	O
at	O
last	O
hospitalization	O
for	O
Afib).	O
EGD	O
at	O
that	O
time	O
was	O
notable	O
for	O
multiple	O
gastric	O
polyps	O
(2-5mm)	O
in	O
fundus	O
and	O
body	O
of	O
stomach	O
and	O
___	O
+	O
bleeding	B-Upper_gastrointestinal_haemorrhage
4cm	O
duodenal	B-Upper_gastrointestinal_haemorrhage
adenoma.	O
He	O
is	O
scheduled	O
to	O
have	O
repeat	O
endoscopy	O
with	O
removal	O
of	O
duodenal	O
adenoma	O
in	O
___.	O
ED	O
Course:	O
===============	O
In	O
the	O
ED	O
initial	O
vitals	O
were:	O
T	O
97.1,	O
HR	O
52,	O
BP	O
96/23,	O
HR	O
22,	O
SpO2	O
96%	O
RA.	O
Exam	O
was	O
notable	O
for:	O
2+	O
___	O
b/l.	O
Guiaic	O
+	O
brown	O
stool	O
on	O
rectal	O
exam.	O
Labs	O
notable	O
for:	O
1.	O
CBC:	O
WBC	O
6.1,	O
Hgb	O
7.0,	O
Plt	O
211.	O
2.	O
BMP:	O
Cr	O
4.4	O
(last	O
Cr	O
2.5	O
on	O
___.	O
3.	O
LFTs:	O
AP	O
elevated	O
137,	O
otherwise	O
nml.	O
4.	O
___:	O
19051	O
5.	O
Lactate:	O
0.7	O
Studies	O
notable	O
for:	O
EKG	O
___	O
(my	O
read):	O
HR	O
56	O
(Sinus	O
brady),	O
nml	O
axis,	O
___	O
degree	O
block	O
(PR	O
266msec),	O
LBBB	O
though	O
w/	O
positive	O
V1	O
deflection(QRS:	O
125msec).	O
___	O
CXR:	O
Worsening	O
moderate	O
bilateral	O
pleural	O
effusions	O
with	O
associated	O
compressive	O
atelectasis.	O
No	O
focal	O
consolidation	O
in	O
remaining	O
visualized	O
lungs.	O
No	O
frank	O
pulmonary	O
edema.	O
Patient	O
was	O
given:	O
Nothing.	O
Vitals	O
on	O
transfer:	O
97.4,	O
HR	O
52,	O
BP	O
132/48,	O
RR	O
20,	O
SpO2	O
94%	O
2L	O
NC	O
Past	O
Medical	O
History:	O
CORONARY	O
ARTERY	O
DISEASE	O
ANEMIA	O
CONGESTIVE	O
HEART	O
FAILURE,	O
DIASTOLIC	O
HYPERLIPIDEMIA	O
HYPERTENSION	O
DIABETES	O
TYPE	O
II	O
DIABETIC	O
NEUROPATHY	O
DIABETIC	O
NEPHROPATHY	O
DIABETIC	O
RETINOPATHY	O
OBESITY	O
PERIPHERAL	O
VASCULAR	O
DISEASE	O
Social	O
History:	O
___	O
Family	O
History:	O
His	O
mother	O
died	O
in	O
her	O
___.	O
HIs	O
father	O
died	O
at	O
about	O
___	O
of	O
an	O
aneurysm.	O
He	O
had	O
type	O
II	O
diabetes.	O
He	O
has	O
a	O
brother	O
and	O
sister,	O
both	O
of	O
whom	O
have	O
type	O
II	O
diabetes.	O
Physical	O
Exam:	O
ADMISSION	O
PHYSICAL	O
EXAM:	O
========================	O
VS:	O
97.4,	O
121/66,	O
HR	O
61,	O
RR	O
20,	O
___	O
NCL	O
GENERAL:	O
Mildly	O
uncomfortable,	O
on	O
2L	O
NC.	O
HEENT:	O
NCAT.	O
NECK:	O
Supple.	O
JVP	O
of	O
15cm	O
H2O	O
(at	O
mandible)	O
CARDIAC:	O
Normal	O
S1,	O
S2.	O
No	O
murmurs,	O
rubs,	O
or	O
gallops.	O
LUNGS:	O
2L	O
NC.	O
Decreased	O
bibasilar	O
breath	O
sounds.	O
ABDOMEN:	O
Soft,	O
non-tender,	O
non-distended.	O
EXTREMITIES:	O
Warm,	O
well	O
perfused.	O
___	O
___	O
up	O
to	O
knees	O
b/l	O
(worse	O
on	O
L	O
>	O
R,	O
pt	O
reports	O
this	O
is	O
chronic).	O
L	O
foot	O
bandaged	O
(ulcer	I-Pressure_injury
on	O
plantar	O
aspect	O
of	O
L.	O
foot)	B-Pressure_injury
SKIN:	O
Chronic	O
venous	O
stasis	O
changes	O
with	O
b/l	O
longtidunal	O
surgical	O
scars	O
along	O
the	O
medial	O
aspect	O
of	O
the	O
calves	O
(s/p	O
fem-pop	O
bypass	O
x2)	O
DISCHARGE	O
PHYSICAL	O
EXAM:	O
========================	O
24	O
HR	O
Data	O
Temp:	O
98.2	O
(Tm	O
99.0),	O
BP:	O
123/64	O
(105-153/58-73),	O
HR:	O
72	O
(72-86),	O
RR:	O
18	O
(___),	O
O2	O
sat:	O
93%	O
(93-96),	O
O2	O
delivery:	O
Ra,	O
Wt:	O
208.33	O
lb/94.5	O
kg	O
Fluid	O
Balance	O
Last	O
24	O
hours	O
Total	O
cumulative	O
130ml	O
IN:	O
Total	O
430ml,	O
PO	O
Amt	O
430ml	O
OUT:	O
Total	O
300ml,	O
Urine	O
Amt	O
300ml,	O
L	O
Chest	O
tube	O
0ml	O
GENERAL:	O
NAD.	O
HEENT:	O
JVD	O
8cm	O
H20	O
CARDIAC:	O
Normal	O
rate,	O
regular	O
rhythm.	O
No	O
m/r/g	O
LUNGS:	O
Decreased	O
breath	O
sounds	O
R	O
base.	O
ABDOMEN:	O
Soft,	O
non-tender,	O
non-distended.	O
EXTREMITIES:	O
1+	O
non-pitting	O
___	O
edema	O
b/l	O
to	O
knees,	O
WWP.	O
L	O
forearm	O
edematous	O
with	O
ecchymosis.	O
Pertinent	O
Results:	O
ADMISSION	O
LABS:	O
===============	O
___	O
04:36PM	O
BLOOD	O
WBC-6.1	O
RBC-2.62*	O
Hgb-7.0*	O
Hct-22.1*	O
MCV-84	O
MCH-26.7	O
MCHC-31.7*	O
RDW-17.0*	O
RDWSD-51.8*	O
Plt	O
___	O
___	O
04:36PM	O
BLOOD	O
Neuts-81.3*	O
Lymphs-8.8*	O
Monos-7.4	O
Eos-1.8	O
Baso-0.2	O
Im	O
___	O
AbsNeut-4.92	O
AbsLymp-0.53*	O
AbsMono-0.45	O
AbsEos-0.11	O
AbsBaso-0.01	O
___	O
04:36PM	O
BLOOD	O
Plt	O
___	O
___	O
04:36PM	O
BLOOD	O
Glucose-181*	O
UreaN-117*	O
Creat-4.4*#	O
Na-136	O
K-4.0	O
Cl-98	O
HCO3-22	O
AnGap-16	O
___	O
04:36PM	O
BLOOD	O
estGFR-Using	O
this	O
___	O
04:36PM	O
BLOOD	O
ALT-27	O
AST-29	O
AlkPhos-137*	O
TotBili-0.6	O
___	O
04:36PM	O
BLOOD	O
Lipase-32	O
___	O
04:36PM	O
BLOOD	O
CK-MB-3	O
cTropnT-0.04*	O
___	O
___	O
04:36PM	O
BLOOD	O
Albumin-3.7	O
Calcium-9.1	O
Phos-6.5*	O
Mg-2.5	O
___	O
07:10PM	O
BLOOD	O
Lactate-0.7	O
INTERVAL	O
LABS:	O
==============	O
___	O
03:18AM	O
BLOOD	O
calTIBC-269	O
Ferritn-183	O
TRF-207	O
___	O
04:08PM	O
BLOOD	O
HBsAg-NEG	O
HBsAb-NEG	O
HBcAb-NEG	O
___	O
03:35PM	O
BLOOD	O
C3-116	O
C4-15	O
___	O
04:08PM	O
BLOOD	O
HIV	O
Ab-NEG	O
___	O
04:08PM	O
BLOOD	O
HCV	O
Ab-NEG	O
DISCHARGE	O
LABS:	O
===============	O
___	O
06:28AM	O
BLOOD	O
WBC-10.7*	O
RBC-3.61*	O
Hgb-9.8*	O
Hct-30.3*	O
MCV-84	O
MCH-27.1	O
MCHC-32.3	O
RDW-16.4*	O
RDWSD-50.5*	O
Plt	O
___	O
___	O
06:28AM	O
BLOOD	O
___	O
PTT-27.7	O
___	O
___	O
06:28AM	O
BLOOD	O
Glucose-341*	O
UreaN-41*	O
Creat-2.4*	O
Na-133*	O
K-4.1	O
Cl-94*	O
HCO3-27	O
AnGap-12	O
___	O
06:28AM	O
BLOOD	O
Calcium-8.2*	O
Phos-2.0*	O
Mg-2.0	O
MICROBIOLOGY:	O
=============	O
L	O
pleural	O
fluid	O
GRAM	O
STAIN	O
(Final	O
___:	O
NO	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
SEEN.	O
NO	O
MICROORGANISMS	O
SEEN.	O
R	O
pleural	O
fluid	O
GRAM	O
STAIN	O
(Final	O
___:	O
NO	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
SEEN.	O
NO	O
MICROORGANISMS	O
SEEN.	O
___:	O
S.	O
aureus	O
Negative;	O
MRSA	O
Negative.	O
STUDIES/IMAGING:	O
================	O
CXR	O
___:	O
Worsening	O
moderate	O
bilateral	O
pleural	O
effusions	O
with	O
associated	O
compressive	O
atelectasis.	O
No	O
focal	O
consolidation	O
in	O
remaining	O
visualized	O
lungs.	O
No	O
frank	O
pulmonary	O
edema.	O
pMIBI	O
___:	O
1.	O
Fixed,	O
medium	O
sized,	O
moderate	O
severity	O
perfusion	O
defect.	O
2.	O
Increased	O
left	O
ventricular	O
cavity	O
size.	O
Mid	O
and	O
basal	O
inferior	O
hypokinesis	O
with	O
preserved	O
systolic	O
function.	O
EUS	O
___:	O
Normal	O
mucosa	O
in	O
esophagus,	O
erythema	O
in	O
the	O
stomach	O
compatible	O
with	O
gastritis,	O
3cm	O
polyp	O
in	O
second	O
part	O
of	O
the	O
duodenum.	O
EUS	O
with	O
no	O
evidence	O
of	O
invasive	O
disease.	O
Successful	O
EMR	O
and	O
clipping.	O
GI	O
pathology	O
___:	O
Adenoma,	O
low-grade	O
with	O
focal	O
high-grade	O
dysplasia,	O
with	O
focal	O
erosion.	O
-No	O
adenomatous	O
epithelium	O
seen	O
at	O
the	O
inked,	O
cauterized	O
tissue	O
margin.	O
VENOUS	O
DUP	O
UPPER	O
EXT	O
BILATERAL	O
Study	O
Date	O
of	O
___	O
Patent	O
right	O
cephalic	O
vein	O
from	O
the	O
antecubital	O
fossa	O
distally,	O
and	O
basilic	O
vein	O
from	O
the	O
antecubital	O
fossa	O
proximally	O
with	O
measurements	O
as	O
above.	O
Patent	O
left	O
cephalic	O
vein	O
with	O
measurements	O
as	O
above.	O
Patent	O
basilic	O
vein	O
proximal	O
to	O
the	O
antecubital	O
fossa	O
with	O
mild	O
wall	O
thickening	O
in	O
the	O
mid	O
arm.	O
Calcification	O
of	O
the	O
bilateral	O
radial	O
arteries	O
with	O
normal	O
peak	O
systolic	O
velocities.	O
Minimal	O
calcification	O
of	O
the	O
bilateral	O
brachial	O
arteries.	O
UNILAT	O
UP	O
EXT	O
VEINS	O
US	O
LEFT	O
Study	O
Date	O
of	O
___	O
No	O
evidence	O
of	O
deep	O
vein	O
thrombosis	O
in	O
the	O
left	O
upper	O
extremity.	O
There	O
is	O
edema	O
in	O
the	O
soft	O
tissues	O
of	O
the	O
upper	O
left	O
arm.	O
CT	O
CHEST	O
W/O	O
CONTRAST	O
Study	O
Date	O
of	O
___	O
1.	O
Status	O
post	O
placement	O
of	O
a	O
catheter	O
in	O
the	O
right	O
pleural	O
space.	O
New	O
moderate	O
right	O
hydropneumothorax.	O
2.	O
Moderate	O
left	O
pleural	O
effusion.	O
3.	O
Few	O
ground-glass	O
opacities	O
and	O
atelectasis	O
in	O
the	O
right	O
lower	O
lobe	O
that	O
could	O
be	O
related	O
to	O
focal	O
aspiration	O
or	O
pulmonary	O
edema.	O
Brief	O
Hospital	O
Course:	O
Mr.	O
___	O
is	O
a	O
___	O
y.o.	O
male	O
patient	O
with	O
HFpEF	O
(EF	O
57%	O
___,	O
CAD,	O
HTN,	O
PVD,	O
IDDM	O
c/b	O
L	O
plantar	O
foot	B-Pressure_injury
ulcer,	B-Pressure_injury
and	O
Stage	O
3	O
CKD	O
with	O
recent	O
admission	O
___	O
for	O
CHF	O
exacerbation	O
who	O
presented	O
to	O
ED	O
on	O
___	O
for	O
dyspnea,	O
reported	O
weight	O
gain,	O
lower	O
extremity	O
edema	O
and	O
was	O
subsequently	O
admitted	O
to	O
Inpatient	O
HF	O
Service	O
on	O
___	O
for	O
acute	O
decompensated	O
HFrEF	O
and	O
___	O
on	O
Stage	O
3	O
CKD.	O
Hospital	O
course	O
was	O
complicated	O
by	O
persistent	O
volume	O
overload	O
and	O
dyspnea	O
requiring	O
initiation	O
of	O
hemodialysis.	O
===============	O
ACTIVE	O
ISSUES:	O
===============	O
#	O
Acute	O
Decompensated	O
HFpEF	O
Presented	O
with	O
acute	O
on	O
chronic	O
dyspnea	O
and	O
weight	O
gain	O
-	O
last	O
discharge	O
weight:	O
106.9	O
kg	O
(235.67lbs)	O
(___).	O
Presented	O
with	O
dyspnea	O
on	O
exertion,	O
weight	O
gain,	O
and	O
lower	O
extremity	O
swelling	O
c/w	O
ADHFpEF.	O
Unclear	O
etiology	O
for	O
this	O
admission,	O
though	O
suspect	O
fluid	O
overload	O
may	O
be	O
___	O
___	O
on	O
CKD	O
(Cr	O
4.4	O
at	O
admission	O
(___),	O
compared	O
to	O
Cr	O
2.5	O
on	O
___.	O
Trop	O
peaked	O
@0.04	O
on	O
___,	O
CKMB	O
3.	O
BNP:	O
19051	O
(13113	O
at	O
last	O
admission).	O
___	O
pMIBI:	O
Fixed	O
medium	O
sized	O
moderate	O
severity	O
perfusion	O
defect.	O
Cath	O
was	O
not	O
performed	O
given	O
___.	O
Actively	O
diuresed	O
with	O
Bumex	O
gtt,	O
though	O
was	O
discontinued	O
due	O
to	O
diffuse	O
myalgias	O
and	O
instead	O
given	O
Lasix	O
+	O
started	O
HD	O
for	O
volume	O
removal.	O
On	O
___,	O
pt	O
was	O
triggered	O
for	O
dyspnea	O
and	O
hypoxemia,	O
and	O
was	O
sent	O
to	O
the	O
CCU	O
for	O
BiPAP.	O
In	O
the	O
CCU	O
he	O
was	O
continued	O
on	O
a	O
Lasix	O
drip	O
and	O
was	O
continued	O
with	O
daily	O
HD.	O
Lasix	O
drip	O
was	O
discontinued	O
on	O
___	O
due	O
to	O
inadequate	O
response.	O
His	O
afterload	O
regimen	O
was	O
titrated	O
to	O
the	O
following:	O
labetalol	O
600	O
TID	O
was	O
discontinued	O
and	O
he	O
was	O
started	O
on	O
metoprolol	O
succinate	O
50mg	O
daily;	O
hydralazine	O
was	O
held;	O
amlodipine	O
10	O
mg	O
daily	O
was	O
continued.	O
#	O
Acute	O
on	O
chronic	O
Anemia	O
#	O
___	O
esophagus	O
#	O
Duodenal	O
Mass	O
Hgb	O
7.0	O
at	O
admission	O
___	O
in	O
past	O
year).	O
Likely	O
mixed	O
with	O
AoCD	O
___	O
CKD	O
and	O
iron	O
deficiency	O
based	O
on	O
prior	O
iron	O
studies.	O
___	O
EGD	O
notable	O
for	O
multiple	O
gastric	O
polyps	O
(2-5mm)	O
in	O
fundus	O
and	O
body	O
of	O
stomach	O
and	O
___	O
+	O
bleeding	B-Upper_gastrointestinal_haemorrhage
4cm	O
duodenal	B-Upper_gastrointestinal_haemorrhage
adenoma.	O
s/p	O
EGD	O
___	O
with	O
removal	O
of	O
duodenal	O
adenoma.	O
s/p	O
1U	O
pRBC	O
on	O
___	O
for	O
Hgb	O
6.8,	O
1U	O
pRBC	O
on	O
___.	O
GI	O
followed	O
closely	O
given	O
concern	O
for	O
reported	O
melena	B-Upper_gastrointestinal_haemorrhage
48	O
hours	O
after	O
EGD/duodenal	O
adenoma	O
removal	O
and	O
low	O
Hgb	O
~7.	O
Hep	O
gtt	O
(for	O
Afib)	O
was	O
briefly	O
paused	O
for	O
24	O
hours	O
after	O
EGD	B-Upper_gastrointestinal_haemorrhage
due	O
to	O
concern	O
for	O
ongoing	O
bleeding,	B-Upper_gastrointestinal_haemorrhage
but	O
was	O
restarted	O
given	O
stable	O
H/H	O
and	O
hemodynamic	O
stability.	O
Otherwise,	O
continued	O
on	O
Protonix	O
bid,	O
and	O
received	O
ferrlecit	O
125mg	O
x	O
8	O
doses	O
(per	O
Renal	O
-	O
___.	O
On	O
arrival	O
to	O
the	O
CCU	O
patient's	O
hemoglobin	O
was	O
noted	O
to	O
be	O
downtrending	O
in	O
the	O
setting	O
of	O
melanic	B-Upper_gastrointestinal_haemorrhage
stool.	O
He	O
remained	O
hemodynamically	O
stable	O
but	O
required	O
2	O
transfusion	O
(___).	O
His	O
heparin	O
drip	O
(started	O
for	O
Afib)	O
was	O
held	O
and	O
repeat	O
EGD	B-Upper_gastrointestinal_haemorrhage
was	O
performed	O
on	O
___	O
which	O
showed	O
clot	O
at	O
site	O
where	O
adenoma	O
was	O
removed,	O
no	O
active	B-Upper_gastrointestinal_haemorrhage
bleeding.	B-Upper_gastrointestinal_haemorrhage
Epi	O
was	O
injected	O
and	O
clips	O
were	O
placed.	O
Patient's	O
hemoglobin	O
stabilized	O
and	O
he	O
had	O
no	O
further	O
episodes	O
of	O
melena.	B-Upper_gastrointestinal_haemorrhage
#	O
pAF	O
(CHADS2VASC	O
6).	O
Diagnosed	O
at	O
last	O
admission	O
(___)	O
and	O
spontaneously	O
converted	O
to	O
NSR.	O
Started	O
Eliquis	O
5mg	O
bid	O
at	O
last	O
admission;	O
however,	O
this	O
was	O
c/b	O
GI	B-Upper_gastrointestinal_haemorrhage
bleed	B-Upper_gastrointestinal_haemorrhage
(melena).	O
Per	O
GI	O
recs,	O
hep	O
gtt	O
was	O
started	O
48	O
hours	O
after	O
duodenal	O
adenoma	O
removal	O
on	O
___	O
(see	O
below).	O
Hep	O
gtt	O
was	O
briefly	O
held	O
due	O
to	O
concern	O
for	O
ongoing	O
GI	B-Upper_gastrointestinal_haemorrhage
bleeding,	B-Upper_gastrointestinal_haemorrhage
then	O
restarted,	O
but	O
held	O
again	O
when	O
he	O
developed	O
further	O
transfusion	O
requirements	O
in	O
the	O
CCU	O
as	O
described	O
above.	O
Once	O
patient's	O
hemoglobin	O
stabilized,	O
he	O
was	O
started	O
on	O
warfarin	O
without	O
a	O
bridge	O
due	O
to	O
recent	O
GI	B-Upper_gastrointestinal_haemorrhage
bleeding.	B-Upper_gastrointestinal_haemorrhage
For	O
rate	O
control,	O
he	O
was	O
transitioned	O
from	O
home	O
labetalol	O
600mg	O
tid	O
to	O
metoprolol	O
succinate	O
50mg	O
daily.	O
#	O
Hypertension	O
Initaially	O
continued	O
home	O
labetalol	O
600	O
mg	O
TID,	O
amlodipine	O
10	O
mg	O
daily,	O
hydralazine	O
to	O
50	O
mg	O
TID.	O
In	O
the	O
CCU	O
labetalol	O
was	O
discontinued	O
and	O
hydralazine	O
held	O
due	O
to	O
low	O
blood	O
pressures.	O
In	O
place	O
of	O
labetalol	O
he	O
was	O
started	O
on	O
metoprolol	O
as	O
above.	O
#	O
___	O
on	O
Stage	O
III	O
CKD	O
p/w	O
Cr	O
4.4	O
at	O
admission	O
(___),	O
compared	O
to	O
Cr	O
2.5	O
on	O
___.	O
Suspected	O
cardiorenal	O
at	O
this	O
time,	O
though	O
may	O
have	O
pre-renal	O
component	O
as	O
well	O
based	O
on	O
reported	O
h/o	O
poor	O
intake	O
and	O
diarrhea	O
___	O
BMs	O
in	O
the	O
past	O
few	O
days	O
prior	O
to	O
admission).	O
Baseline	O
creatinine	O
has	O
fluctuated	O
significantly	O
in	O
the	O
last	O
year	O
iso	O
of	O
multiple	O
heart	O
failure	O
exacerbations.	O
Recent	O
low	O
was	O
1.9	O
in	O
___.	O
Given	O
persistent	O
volume	O
overload/dyspnea	O
despite	O
aggressive	O
diuresis,	O
HD	O
was	O
initiated	O
on	O
___.	O
PPD	O
was	O
placed/read	O
(no	O
induration)	O
and	O
hepatitis	O
serologies	O
were	O
obtained;	O
Hep	O
B	O
booster	O
was	O
administered.	O
Discharged	O
on	O
Sevelamer	O
800mg	O
TID.	O
Patient	O
did	O
not	O
have	O
adequate	O
recovery	O
of	O
his	O
renal	O
function	O
during	O
this	O
admission.	O
A	O
tunneled	O
dialysis	O
catheter	O
was	O
placed	O
and	O
he	O
will	O
be	O
continuing	O
dialysis	O
as	O
an	O
outpatient	O
on	O
a	O
TuThSat	O
schedule.	O
#	O
IDDM	O
Has	O
a	O
h/o	O
poorly	O
controlled	O
blood	O
sugars.	O
At	O
his	O
last	O
admission,	O
FSBG	O
up	O
to	O
300s	O
for	O
which	O
___	O
was	O
c/s.	O
Triggered	O
on	O
morning	O
of	O
___	O
for	O
AMS	O
___	O
hypoglycemia	O
(evening	O
prior,	O
pt	O
had	O
FSBG>500).	O
___	O
was	O
consulted.	O
Final	O
recs	O
were	O
as	O
follows:	O
lantus	O
15U	O
qAM,	O
lantus	O
10U	O
qPM,	O
Humalog	O
6U	O
with	O
meals.	O
#Pleural	O
effusions	O
Patient	O
had	O
bilateral	O
pleural	O
effusions	O
leading	O
to	O
shortness	O
of	O
breath	O
and	O
hypoxia,	O
though	O
to	O
be	O
secondary	O
to	O
CHF	O
and	O
volume	O
overload.	O
He	O
underwent	O
R	O
thoracentesis	O
on	O
___	O
and	O
L	O
thoracentesis	O
on	O
___	O
after	O
which	O
he	O
no	O
long	O
had	O
a	O
supplemental	O
oxygen	O
requirement.	O
He	O
will	O
follow	O
up	O
with	O
interventional	O
pulmonology	O
to	O
monitor	O
for	O
re-accumulation.	O
#	O
Urinary	O
retention	O
Started	O
Flomax	O
0.4mg	O
qhs	O
===============	O
RESOLVED	O
ISSUES:	O
===============	O
#	O
Diffuse	O
joint	O
pain	O
Reported	O
diffuse	O
joint	O
pain	O
shortly	O
after	O
starting	O
Bumex	O
gtt	O
which	O
was	O
subsequently	O
stopped	O
in	O
favor	O
of	O
Lasix	O
gtt	O
due	O
to	O
his	O
pain.	O
Resolved	O
off	O
Bumex.	O
#	O
Diarrhea	O
At	O
admission,	O
reported	O
___	O
per	O
day	O
for	O
the	O
past	O
few	O
days	O
prior	O
to	O
admission.	O
Resolved.	O
===============	O
CHRONIC	O
ISSUES:	O
===============	O
#	O
Left	O
diabetic	O
medial	O
plantar	O
foot	B-Pressure_injury
ulcer	B-Pressure_injury
Left	O
foot	B-Pressure_injury
has	O
~1.5cm	O
ulcer	B-Pressure_injury
on	O
medial	O
plantar	O
surface	O
of	O
left	O
foot.	O
Followed	O
by	O
outpatient	O
Podiatry.	O
Seen	O
by	O
Inpatient	O
Wound	O
Care	O
who	O
agreed	O
with	O
outpatient	O
Wound	O
Care	O
___	O
recs	O
(___):	O
NSW	O
to	O
left	O
foot	B-Pressure_injury
wound,	B-Pressure_injury
pat	O
dry	O
and	O
apply	O
Aquacel	O
AG	O
to	O
wound	O
bed	O
and	O
covered	O
by	O
3x3	O
silicone	O
bordered	O
foam	O
3	O
x	O
weekly.	O
Apply	O
removable	O
felted	O
foam.	O
Dressing	O
changes	O
every	O
other	O
day.	O
#	O
CAD	O
#	O
PVD	O
s/p	O
femoral	O
bypass	O
x2	O
Continued	O
home	O
ASA	O
81mg	O
qd	O
+	O
Atorvastatin	O
80mg	O
qhs.	O
#	O
Gout	O
Continued	O
allopurinol	O
___	O
qod	O
TRANSITIONAL	O
ISSUES	O
===================	O
-	O
EGD	O
pathology	O
(___)	O
showing	O
low	O
grade	O
dysplasia	O
with	O
focal	O
high-grade	O
dysplasia,	O
recommend	O
repeat	O
EGD	O
in	O
6	O
months	O
for	O
surveillance.	O
-	O
continue	O
hepatitis	O
B	O
vaccination	O
series	O
(s/p	O
first	O
dose	O
___	O
-	O
consider	O
cMRI	O
to	O
further	O
evaluate	O
possible	O
AR	O
-	O
10	O
cm	O
intramuscular	O
lipoma	O
in	O
the	O
right	O
posterior	O
chest	O
wall.	O
Given	O
its	O
size,	O
a	O
dedicated	O
MRI	O
could	O
be	O
considered.	O
-	O
IP	O
follow	O
up	O
/	O
further	O
management	O
of	O
large	O
pleural	O
effusion	O
/	O
chest	O
tube	O
-	O
follow	O
up	O
pleural	O
fluid	O
cytology	O
results	O
-	O
Blood	O
sugars	O
remained	O
above	O
goal	O
prior	O
to	O
discharge.	O
Continue	O
close	O
glucose	O
monitoring	O
and	O
insulin	O
titration.	O
[]DISCHARGE	O
WEIGHT:	O
208	O
lbs.	O
[]DISCHARGE	O
CR:	O
2.4	O
[]DISCHARGE	O
Hgb:	O
9.8	O
#	O
LANGUAGE:	O
___	O
#	O
CODE	O
STATUS:	O
Full	O
Code	O
(confirmed	O
with	O
pt	O
on	O
___	O
#	O
HCP:	O
Mairetta	O
___,	O
___	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Allopurinol	O
___	O
mg	O
PO	O
EVERY	O
OTHER	O
DAY	O
2.	O
amLODIPine	O
10	O
mg	O
PO	O
DAILY	O
3.	O
Aspirin	O
81	O
mg	O
PO	O
DAILY	O
4.	O
Atorvastatin	O
80	O
mg	O
PO	O
QPM	O
5.	O
Bisacodyl	O
10	O
mg	O
PO	O
DAILY:PRN	O
Constipation	O
-	O
Second	O
Line	O
6.	O
Brimonidine	O
Tartrate	O
0.15%	O
Ophth.	O
1	O
DROP	O
LEFT	O
EYE	O
Q8H	O
7.	O
Dorzolamide	O
2%/Timolol	O
0.5%	O
Ophth.	O
1	O
DROP	O
LEFT	O
EYE	O
BID	O
8.	O
Fluticasone	O
Propionate	O
NASAL	O
1	O
SPRY	O
NU	O
BID	O
9.	O
HydrALAZINE	O
50	O
mg	O
PO	O
TID	O
10.	O
Pantoprazole	O
40	O
mg	O
PO	O
Q12H	O
11.	O
Travoprost	O
0.004	O
%	O
Ophth	O
Soln	O
(*NF*)	O
0.004	O
%	O
Other	O
QPM	O
12.	O
Labetalol	O
600	O
mg	O
PO	O
TID	O
13.	O
Torsemide	O
80	O
mg	O
PO	O
BID	O
14.	O
Ferrous	O
Sulfate	O
325	O
mg	O
PO	O
DAILY	O
15.	O
Glargine	O
21	O
Units	O
Breakfast	O
Glargine	O
21	O
Units	O
Bedtime	O
Humalog	O
10	O
Units	O
Breakfast	O
Humalog	O
10	O
Units	O
Lunch	O
Humalog	O
10	O
Units	O
Dinner	O
Insulin	O
SC	O
Sliding	O
Scale	O
using	O
HUM	O
Insulin	O
16.	O
Metolazone	O
Dose	O
is	O
Unknown	O
PO	O
Frequency	O
is	O
Unknown	O
Discharge	O
Medications:	O
1.	O
Metoprolol	O
Succinate	O
XL	O
50	O
mg	O
PO	O
DAILY	O
RX	O
*metoprolol	O
succinate	O
[Toprol	O
XL]	O
50	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
Daily	O
Disp	O
#*30	O
Tablet	O
Refills:*1	O
2.	O
Nephrocaps	O
1	O
CAP	O
PO	O
DAILY	O
RX	O
*B	O
complex	O
with	O
C#20-folic	O
acid	O
[Nephrocaps]	O
1	O
mg	O
1	O
capsule(s)	O
by	O
mouth	O
Daily	O
Disp	O
#*30	O
Capsule	O
Refills:*3	O
3.	O
sevelamer	O
CARBONATE	O
800	O
mg	O
PO	O
TID	O
W/MEALS	O
RX	O
*sevelamer	O
carbonate	O
800	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
Three	O
times	O
a	O
day,	O
with	O
meals	O
Disp	O
#*90	O
Tablet	O
Refills:*3	O
4.	O
Tamsulosin	O
0.4	O
mg	O
PO	O
QHS	O
RX	O
*tamsulosin	O
0.4	O
mg	O
1	O
capsule(s)	O
by	O
mouth	O
At	O
bedtime	O
Disp	O
#*30	O
Capsule	O
Refills:*3	O
5.	O
Warfarin	O
6	O
mg	O
PO	O
DAILY16	O
RX	O
*warfarin	O
[Coumadin]	O
2	O
mg	O
3	O
tablet(s)	O
by	O
mouth	O
Daily	O
Disp	O
#*90	O
Tablet	O
Refills:*0	O
6.	O
Glargine	O
15	O
Units	O
Breakfast	O
Glargine	O
10	O
Units	O
Bedtime	O
Humalog	O
6	O
Units	O
Breakfast	O
Humalog	O
6	O
Units	O
Lunch	O
Humalog	O
6	O
Units	O
Dinner	O
7.	O
Allopurinol	O
___	O
mg	O
PO	O
EVERY	O
OTHER	O
DAY	O
8.	O
amLODIPine	O
10	O
mg	O
PO	O
DAILY	O
9.	O
Aspirin	O
81	O
mg	O
PO	O
DAILY	O
10.	O
Atorvastatin	O
80	O
mg	O
PO	O
QPM	O
11.	O
Bisacodyl	O
10	O
mg	O
PO	O
DAILY:PRN	O
Constipation	O
-	O
Second	O
Line	O
12.	O
Brimonidine	O
Tartrate	O
0.15%	O
Ophth.	O
1	O
DROP	O
LEFT	O
EYE	O
Q8H	O
13.	O
Dorzolamide	O
2%/Timolol	O
0.5%	O
Ophth.	O
1	O
DROP	O
LEFT	O
EYE	O
BID	O
14.	O
Ferrous	O
Sulfate	O
325	O
mg	O
PO	O
DAILY	O
15.	O
Fluticasone	O
Propionate	O
NASAL	O
1	O
SPRY	O
NU	O
BID	O
16.	O
Pantoprazole	O
40	O
mg	O
PO	O
Q12H	O
17.	O
Travoprost	O
0.004	O
%	O
Ophth	O
Soln	O
(*NF*)	O
0.004	O
%	O
Other	O
QPM	O
Discharge	O
Disposition:	O
Home	B-Has_carers
With	B-Has_carers
Service	B-Has_carers
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Acute	O
on	O
chronic	O
diastolic	O
heart	O
failure	O
Acute	O
kidney	O
injury	O
Atrial	O
fibrillation	O
Bilateral	O
pleural	O
effusions	O
Acute	O
on	O
chronic	O
anemia	O
Hypertension	O
Insulin	O
dependent	O
diabetes	O
mellitus	O
Coronary	O
artery	O
disease	O
Gout	O
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
Dear	O
Mr.	O
___,	O
WHY	O
WAS	O
I	O
ADMITTED?	O
==================	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
because	O
you	O
were	O
feeling	O
short	O
of	O
breath,	O
had	O
worsening	O
lower	O
leg	O
swelling,	O
and	O
increased	O
weight	O
gain	O
despite	O
taking	O
medications	O
to	O
remove	O
the	O
additional	O
fluid	O
off	O
your	O
body.	O
WHAT	O
HAPPENED	O
WHILE	O
I	O
WAS	O
HOSPITALIZED?	O
===================================	O
-	O
We	O
gave	O
you	O
IV	O
medications	O
to	O
remove	O
fluid	O
from	O
your	O
lungs	O
and	O
body.	O
-	O
We	O
started	O
you	O
on	O
dialysis	O
to	O
remove	O
the	O
fluid,	O
since	O
you	O
were	O
not	O
getting	O
rid	O
of	O
the	O
fluid	O
on	O
IV	O
medications	O
alone.	O
-	O
You	O
had	O
the	O
fluid	O
around	O
your	O
lungs	O
drained.	O
-	O
You	O
were	O
improved	O
significantly	O
and	O
were	O
ready	O
to	O
leave	O
the	O
hospital.	O
WHAT	O
SHOULD	O
I	O
DO	O
AFTER	O
LEAVING	O
THE	O
HOSPITAL?	O
========================================	O
-	O
Please	O
take	O
your	O
medications	O
as	O
listed	O
in	O
discharge	O
summary	O
and	O
follow	O
up	O
at	O
the	O
listed	O
appointments.	O
-	O
Your	O
weight	O
at	O
discharge	O
is	O
208	O
lbs.	O
Please	O
weigh	O
yourself	O
today	O
at	O
home	O
and	O
use	O
this	O
as	O
your	O
new	O
baseline	O
weight.	O
-	O
Please	O
weigh	O
yourself	O
every	O
day	O
in	O
the	O
morning.	O
Call	O
your	O
doctor	O
if	O
your	O
weight	O
goes	O
up	O
by	O
more	O
than	O
3	O
lbs	O
in	O
one	O
day	O
or	O
5	O
lbs	O
in	O
three	O
days.	O
We	O
wish	O
you	O
the	O
best!	O
-	O
Your	O
___	O
Healthcare	O
Team	O
Followup	O
Instructions:	O
___	O

